The putative application of the peptide is in gastrointestinal bleedings but verification of hemostatic effects seems to require further confirmation. Fiscal year earnings forecarst was revised in excess of 10 billion Yen.
3D Matrix press release, March 13, 2015
3D-Matrix withdraws application of hemostatic peptide TDM-621